ClinicalTrials.gov
ClinicalTrials.gov Menu

A Clinical Trial on the Efficacy of a Combination Herbal Product, Biotropics' Nu Femme, on Menopausal Symptoms and Quality of Life in Women (14NMHB)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02269891
Recruitment Status : Recruiting
First Posted : October 21, 2014
Last Update Posted : August 15, 2018
Sponsor:
Collaborator:
Biotropics Malaysia Berhad
Information provided by (Responsible Party):
KGK Science Inc.

Brief Summary:
The purpose of this study is to assess the effectiveness of an herbal combination product called Nu Femme, on menopausal symptoms in peri-menopausal women.

Condition or disease Intervention/treatment Phase
Menopausal Symptoms Dietary Supplement: Nu Femme Other: Placebo Phase 2

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 100 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Other
Official Title: A Randomized Double-Blind, Placebo-Controlled, Parallel Clinical Trial on the Efficacy of a Combination Herbal Product, Biotropics' Nu Femme, on Menopausal Symptoms and Quality of Life in Women
Study Start Date : October 2014
Estimated Primary Completion Date : September 2018

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Menopause

Arm Intervention/treatment
Experimental: Nu Femme
Two capsules (500mg total) taken once daily in the morning after breakfast for 24 weeks
Dietary Supplement: Nu Femme
Combination product of Labisia pumila and Eurycoma longifolia extracts

Placebo Comparator: Placebo
Two capsules taken once daily in the morning after breakfast for 24 weeks
Other: Placebo



Primary Outcome Measures :
  1. Frequency and severity of hot flashes [ Time Frame: Baseline to week 12 ]
    Assessed based on hot flash symptoms score


Secondary Outcome Measures :
  1. Frequency and severity of joint pain [ Time Frame: Baseline to week 12 ]
    Assessed based on joint pain symptoms score

  2. Frequency and severity of hot flashes [ Time Frame: Baseline to week 24 ]
    Assessed based on hot flash symptoms score

  3. Frequency and severity of hot flashes [ Time Frame: Week 12 to week 24 ]
    Assessed based on hot flash symptoms score

  4. Frequency and severity of joint pain [ Time Frame: Baseline to week 24 ]
    Assessed based on joint pain symptoms score

  5. Frequency and severity of joint pain [ Time Frame: Week 12 to week 24 ]
    Assessed based on joint pain symptoms score

  6. Health related quality of life [ Time Frame: Baseline to weeks 3, 6, 12 and 24 ]
    Assessed using the Menopause Rating Scale (MRS)

  7. Menopause specific quality of life [ Time Frame: Baseline to weeks 3, 6, 12 and 24 ]
    Assessed using the Menopause Specific Quality of Life questionnaire (MENQOL)

  8. Serum hormone concentrations [ Time Frame: Baseline to week 12 ]
    Estradiol-17b, FSH, LH, total testosterone and free testosterone

  9. Serum Lipid Profile [ Time Frame: Baseline to week 12 ]
    Total cholesterol, HDL-C, LDL-C and triglycerides


Other Outcome Measures:
  1. Bone markers [ Time Frame: Baseline to week 12 ]
    NTX and BSALP

  2. Blood safety parameters [ Time Frame: Baseline to week 12 ]
    CBC, electrolytes (Na K CL), glucose, creatinine, BUN, AST, ALT, GGT, bilirubin, Ca, albumin

  3. Pap smear [ Time Frame: Baseline to week 12 ]
    Histological analysis for abnormal cells

  4. Pelvic ultrasound [ Time Frame: Baseline to week 12 ]
    To determine changes in endometrial thickness

  5. Incidence of adverse events [ Time Frame: Baseline to week 12 ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   40 Years to 55 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Female of any race between the ages of 40 and 55 years (inclusive)
  • Experiencing perimenopause (irregular menstrual cycles (>3 months) or cessation of menstrual period for at least 3 months within the last 12 months) OR women in menopause (cessation of menstrual period for at least 12 months).
  • Peri-menopausal women must have an endometrial stripe < 8 mm by ultrasound at screening and menopausal women must have an endometrial stripe < 5 mm. Not required for subjects without an intact uterus.
  • Women with an intact cervix must have a pap smear that is normal within 12 months of screening.
  • Experiences menopausal transition symptoms such as hot flushes, sweating, sleep disturbance, migraine, anxiety, vaginal dryness and sexual problems.
  • Minimum of 4 hot flashes per day or 28 per week
  • Total scores of Menopause Rating Scale ≥17 indicating the menopausal symptoms are moderate or severe
  • TSH screening to exclude undiagnosed hyperthyroidism
  • Willingness and ability to give written informed consent and willingness and ability to understand, to participate and to comply with the study requirements.

Exclusion Criteria:

  • Women with a positive mammogram
  • Significant cardiac history including uncontrolled hypertension (defined as untreated systolic blood pressure > 160 mmHg and/or diastolic blood pressure > 100 mmHg) or current diagnosis of any major diseases of the cardiovascular, hepatic, renal, gastrointestinal, pulmonary or endocrine systems
  • Uncontrolled hyperlipidemia
  • History or current diagnosis of breast cancer or breast cancer in an identical twin, or any cancer (except non-melanomatous skin cancer) diagnosed less than 5 years prior to randomization. Subjects with other cancers in full remission more than 5 years after diagnosis are acceptable with the exceptions of breast cancer or genital organ cancer (e.g., cervical cancer, uterine cancer, endometrial cancer, or ovarian cancer)
  • Uncontrolled diabetes (Type I or Type II)
  • Uncontrolled and/or untreated thyroid disorder
  • History or current diagnosis of any major diseases of the cardiovascular, hepatic, renal, gastrointestinal, pulmonary or endocrine systems
  • History or current diagnosis of autoimmune conditions, immunodeficiency or gynaecological disease
  • Clinically significant mental depression that is not well-controlled in the opinion of the investigator
  • Subject has undergone major surgery within the past one year prior to the randomization visit, except cholecystectomy, and appendectomy
  • Subject smokes more than 15 cigarettes a day
  • History of alcohol or drug abuse within the past year
  • Subject has demonstrated non-compliance with treatment while enrolled in other experimental protocols to which the Investigator has knowledge
  • Subject has a mental disability or significant mental illness, legal incapacity or limited legal capacity or any other lack of fitness, in the Investigator's opinion, to preclude subject's participation in or to complete the study
  • History or findings of undiagnosed abnormal vaginal bleeding within the previous two years prior to the randomization visit, including conditions that, in the Investigator's opinion are likely to be the source of unpredictable vaginal bleeding (i.e. leiomyoma or endometrial polyps)
  • Subject has uterine fibroids (> 2cm) or endometriosis. This assessment will be based on the size of the uterus of each participant and will be assessed by the Qualified Investigator
  • Pregnant, breastfeeding, or planning to become pregnant during the course of the trial
  • Positive urine pregnancy test result
  • Polycystic ovary syndrome (PCOS)
  • History of abnormal Pap smear
  • Significant abnormal liver function as defined as AST and/or ALT > 2 x the upper limit of normal (ULN), and/or bilirubin > 2 x the ULN
  • eGFR <60
  • Bleeding disorders or anaemia of any etiology defined as haemoglobin ≤ 110 g/L
  • Subject has taken any of the following medications in the time periods specified prior to the screening visit and during the study

Sex hormones:

Vaginal rings and vaginal creams, ointments or gels 1 week Transdermal or topical 4 weeks DHEA within 24 weeks Natural supplements advertised to have hormonal effects within 4 weeks Oral within 4 weeks Intrauterine progestin implants within 8 weeks Progestin implants and estrogen alone injections within 12 weeks Injected progestin and estrogen or androgen implants or pellets within 24 weeks

Gonadotropin-releasing hormone (GnRH) agonists within 24 weeks

Selective Estrogen Receptor Modulators (SERMs) within 4 weeks

Glucocorticoids - Chronic high dose (≥ 7.5 mg prednisone per day or equivalent) for the past 12 weeks. Exceptions: Chronic low dose corticosteroid use (< 7.5 mg prednisone per day, or equivalent) is permitted provided the subject has been stabilized on a dose for at least 12 weeks prior to randomization and maintains the current dose and dosing regimen during the study. Acute topical, inhaled, or oral (e.g. dose packs) use is not exclusionary and will be permitted during the course of the study.

Antidepressant and/or antianxiety medications within 4 weeks unless a chronic stable dose has been maintained for greater than 12 weeks. Subject must maintain current dose and dosing regimen during the study. Use of Effexor (Venlafaxine HCl) within 4 weeks is exclusionary. Use of Dixarit (Clonidine HCl) within 2 weeks is exclusionary.

Thyroid or anti-epileptic medications within 12 weeks unless a chronic stable dose has been maintained for greater than 12 weeks prior to randomization. Subjects must maintain current dose and dosing regimen during the study

Use of Prostaglandins within 4 weeks

Other investigational study medications within 4 weeks

Current use of propranolol

Current use of an intrauterine device (IUD)

Use of natural health products, such as primrose oil, black cohosh, soy products, other than vitamin and/or mineral supplements within 4 weeks

  • Known allergy or hypersensitivity to study product ingredients
  • Subjects on a weight reduction program or a medically supervised diet.
  • Unexplained weight loss or weight gain of more than 5 kg in the month prior to randomization
  • Any other condition which in the Investigator's opinion may adversely affect the subject's ability to complete the study or its measures or which may pose significant risk to the subject

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02269891


Contacts
Contact: Mal Evans, PhD (519) 438-9374 ext 239 mevans@kgksynergize.com

Locations
Canada, British Columbia
Manna Research - Vancouver Withdrawn
Vancouver, British Columbia, Canada, V6J 1S3
Canada, Ontario
KGK Synergize Inc. Recruiting
London, Ontario, Canada, N6A 5R8
Contact: Mal Evans, PhD    (519) 438-9374 ext 239    mevans@kgksynergize.com   
Principal Investigator: Tetyana Pelipyagina, MD         
Manna Research - Toronto Recruiting
Toronto, Ontario, Canada, M9W 4L6
Contact: Navneet Arora    416-740-2895      
Canada, Quebec
Manna Research - Quebec Active, not recruiting
Levis, Quebec, Canada, G6W 0M5
Manna Research - Montreal Active, not recruiting
Pointe Claire, Quebec, Canada, H9R 4S3
Sponsors and Collaborators
KGK Science Inc.
Biotropics Malaysia Berhad
Investigators
Principal Investigator: Tetyana Pelipyagina, MD KGK Science Inc.

Responsible Party: KGK Science Inc.
ClinicalTrials.gov Identifier: NCT02269891     History of Changes
Other Study ID Numbers: 14NMHB
First Posted: October 21, 2014    Key Record Dates
Last Update Posted: August 15, 2018
Last Verified: August 2018

Keywords provided by KGK Science Inc.:
Menopausal symptoms
Peri-menopause
Nu Femme
Labisia pumila
Eurycoma longifolia
Hot flash
Joint pain